
BEIJING, Feb. 25 (Xinhua) -- China approved the registration applications of two domestically developed COVID-19 vaccines with conditions, the National Medical Products Administration said Thursday.
An inactivated vaccine from the Wuhan Institute of Biological Products, an affiliate of China National Biotec Group of Sinopharm, was allowed to enter the market on a conditional basis, the administration said.
The administration also conditionally approved the recombinant vaccine for COVID-19 made by CanSino Biologics. It marked the first approved adenoviral vector vaccine for COVID-19.
Fire brigade in Shanghai holds group wedding
Tourists enjoy ice sculptures in Datan Town, north China
Sunset scenery of Dayan Pagoda in Xi'an
Tourists have fun at scenic spot in Nanlong Town, NW China
Harbin attracts tourists by making best use of ice in winter
In pics: FIS Alpine Ski Women's World Cup Slalom
Black-necked cranes rest at reservoir in Lhunzhub County, Lhasa
China's FAST telescope will be available to foreign scientists in April
"She power" plays indispensable role in poverty alleviation
Top 10 world news events of People's Daily in 2020
Top 10 China news events of People's Daily in 2020
Top 10 media buzzwords of 2020
Year-ender:10 major tourism stories of 2020
No interference in Venezuelan issues
Biz prepares for trade spat
Broadcasting Continent
Australia wins Chinese CEOs as US loses